OBJECTIVE: To describe maternal and umbilical cord blood anti-spike immunoglobulin (Ig)G levels at delivery with coronavirus disease 2019 (COVID-19) vaccination before and during pregnancy and to assess the association of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and a vaccine booster dose with anti-spike maternal and umbilical cord IgG levels. METHODS: We conducted a retrospective cohort study of women with self-reported COVID-19 vaccination (Pfizer-BioNTech, Moderna, or Johnson & Johnson/Janssen), including a booster dose, during or before pregnancy, who delivered at 34 weeks of gestation or more. Maternal and umbilical cord blood samples at delivery were analyzed for semi-quantitative anti-spike IgG. We examined the association between timing of maternal vaccination and maternal and umbilical cord anti-spike levels using a rank sum test. The relationships between a prior history of SARS-CoV-2 infection and maternal and umbilical cord anti-spike IgG levels, and between a booster dose and maternal and umbilical cord anti-spike levels, were also evaluated using a rank sum test. RESULTS: We included data from 1,359 vaccinated pregnant women, including 20 women who received a booster dose, and 1,362 umbilical cord samples. Maternal anti-spike IgG levels were detectable at delivery regardless of timing of vaccination throughout pregnancy among fully vaccinated women; however, early third-trimester vaccination was associated with the highest anti-spike IgG levels in maternal and umbilical cord blood. Among women with a history of SARS-CoV-2 infection, maternal and cord blood antibody response achieved with vaccination in early pregnancy was comparable with third-trimester vaccination in pregnant women without a history of SARS-CoV-2 infection. A booster dose in the third trimester was associated with maternal anti-spike IgG levels greater than third-trimester vaccination in women with or without a history of SARS-CoV-2 infection. DISCUSSION: Vaccination against COVID-19 before and throughout pregnancy was associated with detectable maternal anti-spike IgG levels at delivery. A complete vaccination course, prior history of SARS-CoV-2 infection, and a third-trimester booster dose were associated with the highest maternal and umbilical cord antibody levels.
OBJECTIVE: To describe maternal and umbilical cord blood anti-spike immunoglobulin (Ig)G levels at delivery with coronavirus disease 2019 (COVID-19) vaccination before and during pregnancy and to assess the association of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and a vaccine booster dose with anti-spike maternal and umbilical cord IgG levels. METHODS: We conducted a retrospective cohort study of women with self-reported COVID-19 vaccination (Pfizer-BioNTech, Moderna, or Johnson & Johnson/Janssen), including a booster dose, during or before pregnancy, who delivered at 34 weeks of gestation or more. Maternal and umbilical cord blood samples at delivery were analyzed for semi-quantitative anti-spike IgG. We examined the association between timing of maternal vaccination and maternal and umbilical cord anti-spike levels using a rank sum test. The relationships between a prior history of SARS-CoV-2 infection and maternal and umbilical cord anti-spike IgG levels, and between a booster dose and maternal and umbilical cord anti-spike levels, were also evaluated using a rank sum test. RESULTS: We included data from 1,359 vaccinated pregnant women, including 20 women who received a booster dose, and 1,362 umbilical cord samples. Maternal anti-spike IgG levels were detectable at delivery regardless of timing of vaccination throughout pregnancy among fully vaccinated women; however, early third-trimester vaccination was associated with the highest anti-spike IgG levels in maternal and umbilical cord blood. Among women with a history of SARS-CoV-2 infection, maternal and cord blood antibody response achieved with vaccination in early pregnancy was comparable with third-trimester vaccination in pregnant women without a history of SARS-CoV-2 infection. A booster dose in the third trimester was associated with maternal anti-spike IgG levels greater than third-trimester vaccination in women with or without a history of SARS-CoV-2 infection. DISCUSSION: Vaccination against COVID-19 before and throughout pregnancy was associated with detectable maternal anti-spike IgG levels at delivery. A complete vaccination course, prior history of SARS-CoV-2 infection, and a third-trimester booster dose were associated with the highest maternal and umbilical cord antibody levels.
Authors: Caroline G Atyeo; Lydia L Shook; Sara Brigida; Rose M De Guzman; Stepan Demidkin; Cordelia Muir; Babatunde Akinwunmi; Arantxa Medina Baez; Maegan L Sheehan; Erin McSweeney; Madeleine D Burns; Ruhi Nayak; Maya K Kumar; Chinmay D Patel; Allison Fialkowski; Dana Cvrk; Ilona T Goldfarb; Lael M Yonker; Alessio Fasano; Alejandro B Balazs; Michal A Elovitz; Kathryn J Gray; Galit Alter; Andrea G Edlow Journal: Nat Commun Date: 2022-06-28 Impact factor: 17.694
Authors: Natasha B Halasa; Samantha M Olson; Mary A Staat; Margaret M Newhams; Ashley M Price; Julie A Boom; Leila C Sahni; Melissa A Cameron; Pia S Pannaraj; Katherine E Bline; Samina S Bhumbra; Tamara T Bradford; Kathleen Chiotos; Bria M Coates; Melissa L Cullimore; Natalie Z Cvijanovich; Heidi R Flori; Shira J Gertz; Sabrina M Heidemann; Charlotte V Hobbs; Janet R Hume; Katherine Irby; Satoshi Kamidani; Michele Kong; Emily R Levy; Elizabeth H Mack; Aline B Maddux; Kelly N Michelson; Ryan A Nofziger; Jennifer E Schuster; Stephanie P Schwartz; Laura Smallcomb; Keiko M Tarquinio; Tracie C Walker; Matt S Zinter; Suzanne M Gilboa; Kara N Polen; Angela P Campbell; Adrienne G Randolph; Manish M Patel Journal: MMWR Morb Mortal Wkly Rep Date: 2022-02-18 Impact factor: 17.586
Authors: Natasha B Halasa; Samantha M Olson; Mary A Staat; Margaret M Newhams; Ashley M Price; Pia S Pannaraj; Julie A Boom; Leila C Sahni; Kathleen Chiotos; Melissa A Cameron; Katherine E Bline; Charlotte V Hobbs; Aline B Maddux; Bria M Coates; Kelly N Michelson; Sabrina M Heidemann; Katherine Irby; Ryan A Nofziger; Elizabeth H Mack; Laura Smallcomb; Stephanie P Schwartz; Tracie C Walker; Shira J Gertz; Jennifer E Schuster; Satoshi Kamidani; Keiko M Tarquinio; Samina S Bhumbra; Mia Maamari; Janet R Hume; Hillary Crandall; Emily R Levy; Matt S Zinter; Tamara T Bradford; Heidi R Flori; Melissa L Cullimore; Michele Kong; Natalie Z Cvijanovich; Suzanne M Gilboa; Kara N Polen; Angela P Campbell; Adrienne G Randolph; Manish M Patel Journal: N Engl J Med Date: 2022-06-22 Impact factor: 176.079